In the current study, we investigated the expression of EHD1 in 214 NSCLC patients and its relationship with lymph node metastasis and clinical outcome (overall survival [OS], disease-free survival [DFS]). This evidence concerns the gene EHD1 and metastatic malignant neoplasm in the lymph nodes.